< Back to 68k.news US front page

2nd dose of J&J vaccine boosts protection against moderate to severe COVID-19 to 94% in US study, company says

Original source (on modern site)

A man receiving a J&J vaccine. KAMIL KRZACZYNSKI / Contributor/Getty Images

Johnson & Johnson on Tuesday said a second dose of its COVID-19 vaccine was highly effective against moderate to severe COVID-19.

The company said in a press release, citing its own studies, that two doses provided:

The second dose was administered about two months after the first dose, the company said. For context, Moderna's COVID-19 vaccine was given 28 days apart and Pfizer-BioNTech's 21 days apart in trials. There's some evidence that those two shots have worked better in countries, such as the UK, that delayed the second dose.

The J&J figures are based on a 30,000-patient study, called Ensemble 2, in which a second dose was given to volunteers 56 days apart, STAT News reported.

To get the top-line figures, J&J said 14 people who received two doses caught moderate to severe COVID-19, compared with 52 people who got the placebo. No one got severe or "critical" COVID-19, the company said.

The data hasn't yet been published or scrutinized by experts in a peer review.

Unlike its single-dose shot, a second dose of J&J's vaccine isn't authorized by the Food and Drug Administration.

A recent observational study from the Centers for Disease Control and Prevention of patients with no immunocompromising conditions at 21 US hospitals estimated that a single shot of the J&J vaccine reduced the risk of hospitalization from COVID-19 by 71%. It estimated two doses of Moderna's and Pfizer-BioNTech's shots reduced the risk by 93% and 88%.

Read the original article on Business Insider

< Back to 68k.news US front page